Sign In
Buy LLY
$1,185.71
-7.09 (-0.594%)
At Close: Aug 07, 2026
Eli Lilly's Alzheimer's Therapy's Broad Label Reflects Regulatory Confidence in Anti-Amyloid Antibodies: Analyst
12:13pm, Wednesday, 03'rd Jul 2024
On Tuesday, the FDA approved Eli Lilly and Co's LLY Kisunla (donanemab) once-monthly injection for IV infusion) for adults with early symptomatic Alzheimer's disease.
FDA Approves Eli Lilly's Alzheimer's Drug Kisunla
11:35am, Wednesday, 03'rd Jul 2024
Eli Lilly (LLY) has received Food and Drug Administration (FDA) approval for its treatment for early symptomatic Alzheimer's after studies showed that the drug was able to slow the progression of the
Eli Lilly (LLY) Hits Highs After FDA Approves Its Alzheimer's Treatment
11:32am, Wednesday, 03'rd Jul 2024
Eli Lilly (LLY) hit a new all-time high today as the FDA approved its Alzheimer's treatment “Kisunla.” The treatment is intended for adults in early symptomatic stages of Alzheimer's disease.
Top 3 Health Care Stocks That May Crash This Quarter
09:41am, Wednesday, 03'rd Jul 2024
As of July 3, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Eli Lilly (LLY) Gets FDA Nod for Alzheimer's Drug Donanemab
09:35am, Wednesday, 03'rd Jul 2024
Eli Lilly's (LLY) Alzheimer's disease drug, Kisunla (donanemab), wins FDA approval. Kisunla will be the second drug on the market to treat the disease.
Lilly follows Biogen-Eisai in securing US FDA approval for Alzheimer's drug
08:34am, Wednesday, 03'rd Jul 2024
Eli Lilly's Kisunla secured standard approval from the U.S. Food and Drug Administration on Tuesday for slowing the progression of Alzheimer's disease.
Analysts revise Eli Lilly stock price targets
07:37am, Wednesday, 03'rd Jul 2024
Eli Lilly (NYSE: LLY) recently made headlines with positive drug trial results for its GLP-1 weight-loss drug and its approval in China. But there might be some potential trouble ahead, as U.S. Presid
FDA approves a new Alzheimer's drug from Eli Lilly
07:37am, Wednesday, 03'rd Jul 2024
Evan Seigerman, BMO Capital Markets senior research analyst, joins 'Squawk Box' to discuss the FDA's approval of Eli Lilly's Alzheimer's drug donanemab, how much revenue it could add to Elil LIlly's b
Eli Lilly Advances Alzheimer's Solutions With Kisunla Approval
06:52am, Wednesday, 03'rd Jul 2024
Eli Lilly's new Alzheimer's drug, Kisunla, shows promise with its unique treatment regimen and potential competitive advantages over Biogen's Leqembi. Despite challenges, Kisunla is priced aggressivel
Eli Lilly's Alzheimer's drug receives FDA sign-off
06:18am, Wednesday, 03'rd Jul 2024
The Food and Drug Administration (FDA) has approved Eli Lilly and Co's (NYSE:LLY) new Alzheimer's drug, donanemab, to be sold under the brand name Kisunla. This monoclonal antibody infusion, administ
Novo Nordisk and Eli Lilly Slide as Biden Blasts Weight-Loss Drug Prices
05:01pm, Tuesday, 02'nd Jul 2024
Novo Nordisk (NVO) American depositary receipts (ADRs) and Eli Lilly (LLY) shares lost ground Tuesday after U.S. President Joe Biden and Senator Bernie Sanders called out the companies in an op-ed for
FDA approves Eli Lilly's Alzheimer's drug Kisunla
04:46pm, Tuesday, 02'nd Jul 2024
Eli Lilly's (LLY) Alzheimer's treatment drug Kisunla has gained approval by the US Food and Drug Administration. Yahoo Finance Health Reporter Anjalee Khemlani expands on Kisunla's results in slowing
3-Stock Lunch: Eli Lilly, Paypal, & Paramount
03:34pm, Tuesday, 02'nd Jul 2024
Boris Schlossberg, managing director of FX strategy at BK Asset Management, joins CNBC's 'Power Lunch' to discuss how to play three stocks: Eli Lilly, Paypal, and Paramount.
Eli Lilly's Alzheimer's drug wins FDA approval
02:59pm, Tuesday, 02'nd Jul 2024
An Eli Lilly & Co. Alzheimer's drug won Food and Drug Administration approval Tuesday, capping the medication's bumpy ride through the U.S. regulatory process and adding a second new treatment option
Eli Lilly Snags Long-Awaited Alzheimer's Drug Approval, Rivaling Biogen, Eisai
02:16pm, Tuesday, 02'nd Jul 2024
Eli Lilly won FDA approval for its Alzheimer's treatment, donanemab, on Tuesday. But Eli Lilly stock remained in the red.
